| Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis |
53 |
| Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
45 |
| Surgical and tissue engineering strategies for articular cartilage and meniscus repair |
44 |
| The IL-1 family of cytokines and receptors in rheumatic diseases |
42 |
| Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction |
42 |
| Intra-articular treatment options for knee osteoarthritis |
39 |
| Shared and distinct mechanisms of fibrosis |
35 |
| Rheumatic immune-related adverse events from cancer immunotherapy |
35 |
| Type I interferon in rheumatic diseases |
35 |
| Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis |
34 |
| Behcet syndrome: a contemporary view |
33 |
| An update on the genetics of hyperuricaemia and gout |
33 |
| New therapies for systemic lupus erythematosus - past imperfect, future tense |
32 |
| Therapeutic options for targeting inflammatory osteoarthritis pain |
32 |
| Classification of myositis |
30 |
| Neuropsychiatric lupus: new mechanistic insights and future treatment directions |
29 |
| Pathogenesis and therapeutic interventions for ANCA-associated vasculitis |
29 |
| Autoantibodies in myositis |
29 |
| Mechanisms, biomarkers and targets for adult-onset Still's disease |
27 |
| B cells in the pathogenesis of primary Sjogren syndrome |
26 |
| Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies |
25 |
| Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition |
24 |
| Inclusion body myositis: clinical features and pathogenesis |
24 |
| Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity |
24 |
| Modern-day environmental factors in the pathogenesis of osteoarthritis |
23 |
| T follicular helper cells and T follicular regulatory cells in rheumatic diseases |
23 |
| Skeletal changes during and after spaceflight |
22 |
| Emerging targets of disease-modifying therapy for systemic sclerosis |
22 |
| Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison |
21 |
| Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis |
20 |
| Update on outcome assessment in myositis |
20 |
| Risk factors and disease mechanisms in myositis |
20 |
| S100 proteins in rheumatic diseases |
20 |
| IL-17 in the immunopathogenesis of spondyloarthritis |
20 |
| Calcium crystal deposition diseases - beyond gout |
20 |
| The B cell response to citrullinated antigens in the development of rheumatoid arthritis |
20 |
| The role of neutrophil extracellular traps in rheumatic diseases |
19 |
| The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis |
19 |
| New insights into the genetics and epigenetics of systemic sclerosis |
19 |
| Systemic effects of IL-17 in inflammatory arthritis |
19 |
| Machine-learning-based patient-specific prediction models for knee osteoarthritis |
18 |
| Cell migration: implications for repair and regeneration in joint disease |
17 |
| Treat-to-target in rheumatoid arthritis - are we there yet? |
16 |
| Autoimmunity and primary immunodeficiency: two sides of the same coin? |
16 |
| Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair |
16 |
| Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? |
16 |
| Microvascular endothelial dysfunction in rheumatoid arthritis |
15 |
| The microbiome and HLA-B27-associated acute anterior uveitis |
15 |
| Pathogenic stromal cells as therapeutic targets in joint inflammation |
15 |
| Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes |
15 |
| New therapeutic strategies in systemic lupus erythematosus management |
15 |
| Biomarkers as drug development tools: discovery, validation, qualification and use |
14 |
| Existing and novel biomarkers for precision medicine in systemic sclerosis |
13 |
| Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management |
13 |
| Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
13 |
| Establishing outcome measures in early knee osteoarthritis |
13 |
| Mouse models for human hyperuricaemia: a critical review |
13 |
| Rheumatic manifestations of chikungunya: emerging concepts and interventions |
13 |
| Pathophysiology, assessment and treatment of psoriatic dactylitis |
13 |
| Treatment in myositis |
13 |
| Preventing progression from arthralgia to arthritis: targeting the right patients |
12 |
| The immunobiology of MIF: function, genetics and prospects for precision medicine |
12 |
| Major lung complications of systemic sclerosis |
12 |
| Antiresorptive and anabolic agents in the prevention and reversal of bone fragility |
12 |
| Nocebos in rheumatology: emerging concepts and their implications for clinical practice |
11 |
| The non-haemostatic role of platelets in systemic lupus erythematosus |
11 |
| The role of semaphorins in immune responses and autoimmune rheumatic diseases |
11 |
| Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis |
10 |
| HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications |
10 |
| Molecular transport in articular cartilage - what have we learned from the past 50 years? |
10 |
| B cell therapy in ANCA-associated vasculitis: current and emerging treatment options |
10 |
| Chemokines in rheumatic diseases: pathogenic role and therapeutic implications |
9 |
| The structure, specificity and function of anti-citrullinated protein antibodies |
9 |
| Joint diseases: from connexins to gap junctions |
9 |
| Moving towards a molecular taxonomy of autoimmune rheumatic diseases |
9 |
| The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA |
9 |
| Mechanisms of lung disease development in rheumatoid arthritis |
8 |
| Spontaneous dog osteoarthritis - a One Medicine vision |
8 |
| IVD progenitor cells: a new horizon for understanding disc homeostasis and repair |
8 |
| Advances in antibody engineering for rheumatic diseases |
7 |
| The role of imaging in the diagnosis and management of axial spondyloarthritis |
6 |
| Nonendocrine mechanisms of sex bias in rheumatic diseases |
6 |
| B cell checkpoints in autoimmune rheumatic diseases |
6 |
| Cannabinoids for the treatment of rheumatic diseases - where do we stand? |
6 |
| Proteinases and their receptors in inflammatory arthritis: an overview |
5 |
| Palindromic rheumatism as part of the rheumatoid arthritis continuum |
5 |
| The RA-MAP Consortium: a working model for academia-industry collaboration |
5 |
| Insights into rheumatic diseases from next-generation sequencing |
5 |
| Stratifying management of rheumatic disease for pregnancy and breastfeeding |
4 |
| Next-generation imaging of the skeletal system and its blood supply |
4 |
| Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis |
4 |
| Single-cell technologies - studying rheumatic diseases one cell at a time |
4 |
| Leukocyte trafficking between stromal compartments: lessons from rheumatoid arthritis |
2 |
| Bedside to bench: defining the immunopathogenesis of psoriatic arthritis |
2 |
